Jiangsu SOPO (Group) Co., Ltd. Overview
| Item | Detail |
|---|---|
| Entity profiled | Jiangsu SOPO Chemical Co., Ltd. (江苏索普化工股份有限公司) |
| Parent / named entity | Jiangsu SOPO (Group) Co., Ltd. (江苏索普(集团)有限公司), unlisted SOE |
| Ultimate controller | Zhenjiang Municipal People's Government SASAC |
| Former names | Group predecessor: Zhenjiang Chemical Plant (镇江化工厂) |
| Founding year | 1958 (group predecessor) |
| Listing | Shanghai Stock Exchange main board, A-shares, since 1996 (IPO raised RMB 87M per 36Kr; listing month variously reported as Aug or Sep 1996) |
| Ticker | 600746 (SSE); also tradable via Shanghai–Hong Kong Stock Connect |
| ISIN | — |
| Incorporation jurisdiction | Jiangsu Province, People's Republic of China |
| Registered address | No. 88 Qiusuo Road, Jingkou District, Zhenjiang, Jiangsu 212006 |
| Office address | No. 101 Qiusuo Road, Jingkou District, Zhenjiang, Jiangsu 212006 |
| Telephone / email | 0511-88995001 / jssopo@sopo.com.cn |
| Website | www.sopo.com.cn |
| Fiscal year end | 31 December |
| Total shares | 1,167,842,884 A-shares (since April 2021), all now tradable |
| Controlling shareholder stake | 867,603,652 shares, 74.29% (May 2024 disclosure) |
| Employees | 2,039 (Simply Wall St) / 2,058 (CFI.cn) |
| Auditor | BDO China Shu Lun Pan CPAs (立信会计师事务所), auditor since FY2024; standard unqualified opinions for FY2024 and FY2025 |
| Chairman | Shao Shouyan (邵守言) |
| General Manager | Chen Zhilin (as listed by Simply Wall St; not cross-verified in a primary filing) |
| Industry (CSRC) | C26 Chemical raw materials and chemical products manufacturing |
| Share price | RMB 6.56 (close 31 Jul 2026); RMB 5.22 (13 Jul 2026, before limit-up on 14 Jul) |
| Market cap | Approx. RMB 7.66bn at RMB 6.56 x 1,167.84M shares (derived, 31 Jul 2026) |
Jiangsu SOPO Chemical is a Zhenjiang-based, state-controlled commodity chemical producer whose economics are dominated by a single product: acetic acid made by methanol carbonylation from coal-derived syngas. It operates 1.2 million tonnes per year of acetic acid and 250,000 tonnes per year of ethyl acetate capacity, placing it among China's larger acetic acid producers, alongside a smaller chlor-alkali, sulfuric acid and fine-chemicals platform held in its wholly owned subsidiary SOPO New Materials. Earnings are highly cyclical: net profit swung from RMB 2.40bn in FY2021 to RMB 18.8M in FY2023 as Chinese acetic acid capacity expanded past 15 million tonnes. Management's response is downstream integration into vinyl acetate monomer (VAM), ethylene-vinyl acetate (EVA) and dimethyl carbonate (DMC), funded by a proposed RMB 1.6bn private placement. The equity is a high-beta, low-float-relative-to-parent vehicle on the acetic acid cycle, with a 74% SOE parent.
Company's own description (FY2025 annual report, paraphrased)
In its FY2025 annual report summary (published 18 April 2026), the company states that its principal business, together with its subsidiaries, is the production and sale of chemical raw materials, chiefly acetic acid and derivatives, and chlor-alkali products. It describes acetic acid and its derivatives as basic chemical feedstocks, handled as liquids in tanks, used across dyes, printing and dyeing, film, solvents, pharmaceuticals and pesticides, and notes that in China acetic acid goes mainly into PTA, acetate esters, vinyl acetate and acetic anhydride.
The company states that its methanol carbonylation route is the mainstream industry technology, that China is the world's largest acetic acid producer with over half of global capacity, and that the business, as a branch of coal chemicals, is cyclical and driven by the macro cycle and upstream/downstream supply-demand. The parent company itself produces glacial acetic acid, ethyl acetate, sulfuric acid and ADC blowing agent; the wholly owned subsidiary Jiangsu SOPO New Materials Technology Co., Ltd. produces chlor-alkali, sulfuric acid, chlorobenzenes, fatty alcohols and chloroacetic acid.
Operationally, the company describes an "amoeba" management model focused on innovation and cost, transparent open procurement with price comparison, and a sales model that is primarily direct sales supplemented by distributors, with an effort to raise the direct-customer share and develop self-operated exports.
Independent characterisation
SOPO Chemical is best understood as a single-product, coal-to-acetic-acid spread business with a small, lower-margin inorganic chemicals tail. The acetic acid and derivatives line generated roughly RMB 1.06–1.07bn of revenue per quarter in Q4 2024 and Q1 2025, against roughly RMB 78–85M for sulfuric acid and derivatives in the same quarters (quarterly operating-data announcements). On those figures acetic acid and derivatives represent roughly 85–90% of quarterly operating revenue, with the remainder split across sulfuric acid, chlor-alkali and fine chemicals.
The company is integrated backward into methanol (methanol output rose 64.94% in FY2024 per the General Manager's report), which is an intermediate for acetic acid and the planned DMC unit. It is not integrated into coal mining, so it is a buyer of coal and therefore benefits when coal prices fall faster than acetic acid prices (as the FY2025 report notes occurred).
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales; no material service, subscription or licensing revenue |
| Value-chain position | Mid-stream: coal/syngas → methanol → acetic acid → ethyl acetate; inorganic chain: sulfur → sulfuric acid; salt → caustic soda/chlorine → chlorobenzenes, chloroacetic acid |
| Pricing | Spot/contract prices referenced to Chinese domestic commodity markets; price-taker |
| Customer types | PTA producers, acetate ester makers, VAM producers, acetic anhydride producers, pharmaceutical and agrochemical intermediates makers, textile/dye users, traders |
| Sales channel | Mainly direct, supplemented by distributors; developing self-operated exports |
| End-markets | Polyester (via PTA), coatings and solvents (esters), adhesives and films (VAM), pharma, pesticides, dyes, light industry, construction materials, power, electronics, food processing |
| Other revenue | "Other revenue" of RMB 86.5M in FY2025, down from RMB 404.2M in FY2021 (StockAnalysis) |
Strategy
Stated strategy themes. The FY2024 General Manager's report framed the year around accelerating "new quality productive forces" and high-quality development, with safety, environmental compliance, cost reduction and capacity utilisation as operating pillars. The FY2025 report emphasises technical retrofits, run optimisation and cost reduction.
Downstream integration. The central strategic initiative is extending from acetic acid and methanol into higher-value products:
Medium-term financial targets: none publicly disclosed.
Products & Services
Acetic acid and derivatives (parent company)
| Product | Description | Capacity | Key uses / customers | Notes |
|---|---|---|---|---|
| Glacial acetic acid | Methanol carbonylation of CO; coal-based syngas | 1,200,000 t/yr | PTA, acetate esters, VAM, acetic anhydride, pharma, pesticides, dyes | Core earnings driver; ranks among leading Chinese producers |
| Ethyl acetate | Esterification of acetic acid with ethanol | 250,000 t/yr | Solvents for coatings, inks, adhesives, pharma | Captive acetic acid consumption |
| Methanol | Intermediate from syngas | — | Captive feed to acetic acid; planned DMC feed | FY2024 output +64.94% YoY |
Other chemicals (mainly SOPO New Materials)
| Product | Capacity | Uses |
|---|---|---|
| Sulfuric acid and downstream series | 600,000 t/yr | Fertiliser, metals, chemicals |
| Caustic soda (chlor-alkali) | 200,000 t/yr | Alumina, pulp, textiles, chemicals |
| Dichlorobenzene | 30,000 t/yr | Intermediates, pesticides, deodorants |
| Chloroacetic acid | 50,000 t/yr | Carboxymethyl cellulose, herbicides, pharma |
| 2-chloro-4-aminotoluene (邻氯对氨基甲苯) | 5,000 t/yr | Dye and pesticide intermediates |
| Fatty alcohols | — | Surfactants |
| ADC blowing agent (azodicarbonamide) | Small; volumes low | Foamed plastics and rubber; now mainly serves legacy customers and blended products |
Pipeline products (pre-revenue)
| Project | Scale | Technology | Status |
|---|---|---|---|
| VAM and EVA integrated project, phase 1 | Not specified in sources reviewed | DuPont ethylene-route VAM licence (company claims it is the only DuPont-licensed VAM technology in China) | Licence acquired from SOPO Group 2024; seeking placement funding |
| 200 kt/yr DMC | 100 kt/yr industrial grade + 100 kt/yr electronic grade | UBE (Japan) technology | Total investment RMB 1.544bn; RMB 700M from placement; 3-year build |
Pricing for all products is market-referenced commodity pricing; no list prices are disclosed.
Financial Narrative
Source: StockAnalysis.com standardised statements (pulled 31 Jul 2026), cross-checked against company announcements for FY2024 and FY2025 revenue and net profit, which match.
Income statement
FY2021 EPS is overstated slightly vs reported weighted EPS because 119.5M shares were issued in April 2021. FY2021 DPS is the RMB 2 per 10 shares paid in 2022 per Jiemian.
Margins
Revenue CAGR FY2021–FY2025 (derived): approx. -7.5% per year. Implied FY2020 revenue (from 110.89% FY2021 growth) is approx. RMB 3.80bn, giving a FY2020–FY2025 CAGR of roughly +9%, consistent with Simply Wall St's 10.5% 5-year revenue growth figure.
Balance sheet (selected)
At 31 March 2026, cash had fallen to RMB 643M and the company moved to net debt of RMB 115M (StockAnalysis), the first net-debt position in the five-year series. The liability-to-asset ratio was 17.69% at 30 June 2024 (Jiemian), indicating a conservatively financed balance sheet.
Cash flow (selected)
H1 2024 operating cash inflow was RMB 155M, up RMB 161M YoY (Jiemian).
Ratios
ROE was reported at 4.5% on a trailing basis in mid-2025 by Simply Wall St.
Commentary
The five-year record is a textbook commodity cycle. FY2021 was exceptional: acetic acid prices in China spiked on supply outages and strong PTA/VAM demand, lifting gross margin to roughly 42% and net profit to RMB 2.40bn. That boom attracted a wave of capacity; by mid-2025 Chinese capacity exceeded 15 million tonnes after more than 2 million tonnes were added in H1 2025 alone, while downstream demand grew only 5–7% (Jiemian, Aug 2025). Gross margin compressed to single digits from FY2023.
FY2024 was a volume-led recovery: acetic acid and derivatives output rose 31.81% and methanol 64.94%, lifting revenue 18.4% and net profit to RMB 213M. FY2025 reversed: management cited heavy new industry capacity, a further fall in acetic acid prices, and a major plant turnaround that reduced output and sales slightly, partly offset by lower coal costs. Net profit fell to RMB 88.4M; with 9M 2025 profit of RMB 126M, Q4 2025 was loss-making (approx. RMB -38M, derived).
The notable cost-side trend is R&D, which more than halved from RMB 271M (FY2022) to RMB 109M (FY2025). SG&A has also been cut. The balance sheet, while still conservative, has shifted from a large net cash pile (RMB 1.88bn in FY2021) toward modest net debt at Q1 2026, as dividends, the licence purchase, project pre-spend and receivables growth (AR up 36% in FY2025) absorbed cash.
The inflection into 2026 is price-driven: H1 2026 net profit is guided at RMB 220–250M, implying Q2 2026 of RMB 186–216M versus RMB 34M in Q1, attributed by the company to higher year-on-year prices of its main products.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Activities |
|---|---|---|
Zhenjiang SASAC | Actual controller | State ownership |
Jiangsu SOPO (Group) Co., Ltd. | Controlling shareholder, 74.29% (May 2024) | Holding company; also owns SOPO Chemical Construction Engineering Co. (petrochemical construction, pressure-vessel qualifications) and SOPO Engineering Technology Co. (chemical design) |
Jiangsu SOPO Chemical Co., Ltd. (600746) | Listed company | Acetic acid, ethyl acetate, sulfuric acid, ADC blowing agent, methanol (intermediate) |
Jiangsu SOPO New Materials Technology Co., Ltd. | 100% subsidiary | Chlor-alkali, sulfuric acid series, chlorobenzenes, fatty alcohols, chloroacetic acid; designated developer of VAM/EVA project |
Product Lines
| Product line (CNY Mn, quarterly) | Q4 2024 | Q1 2025 |
|---|---|---|
Acetic acid and derivatives revenue | 1,059.06 | 1,071.09 |
Sulfuric acid and derivatives revenue | 77.80 | 85.02 |
Product line volume (tonnes, quarterly)
| Product line volume (tonnes, quarterly) | Q4 2024 | Q1 2025 |
|---|---|---|
Acetic acid and derivatives output | 455,526 | 452,424 |
Acetic acid and derivatives sales | 393,831 | 391,230 |
Sulfuric acid and derivatives output | 224,091 | 225,314 |
Sulfuric acid and derivatives sales | 224,616 | 226,801 |
Revenue by Segment
| Segment (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue as reported | 5,406 | 6,403 | 5,856 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue as reported (CNY Mn) | 8,004 | 7,172 | 5,406 | 6,403 | 5,856 |
Operating revenue (CNY Mn) | 7,599 | 6,991 | 5,229 | 6,346 | 5,770 |
Revenue growth (%) | 110.89 | -10.39 | -24.62 | 18.43 | -8.53 |
Cost of revenue (CNY Mn) | 4,671 | 6,110 | 4,996 | 5,842 | 5,536 |
Gross profit (CNY Mn) | 3,333 | 1,062 | 410 | 560 | 320 |
SG&A (CNY Mn) | 139.39 | 197.68 | 200.49 | 178.00 | 152.92 |
R&D expense (CNY Mn) | 256.33 | 270.77 | 199.92 | 146.96 | 109.29 |
Total operating expenses (CNY Mn) | 465.78 | 514.07 | 413.36 | 320.38 | 261.93 |
Operating income, derived (CNY Mn) | 2,867 | 548 | -3 | 240 | 58 |
Net income attributable (CNY Mn) | 2,402 | 505.14 | 18.83 | 213.59 | 88.38 |
Net income growth (%) | 938.45 | -78.97 | -96.27 | 1,034.14 | -58.62 |
Basic EPS, derived on 1167.84M shares (MYR Bn) | 2.06 | 0.43 | 0.02 | 0.18 | 0.08 |
Dividend per share (MYR Bn) | 0.20 | — | — | 0.05 | 0.04 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, derived | 41.6 | 14.8 | 7.6 | 8.7 | 5.5 |
Operating margin, derived | 35.8 | 7.6 | -0.1 | 3.7 | 1.0 |
Net margin | 30.0 | 7.0 | 0.35 | 3.3 | 1.5 |
R&D / revenue, derived | 3.2 | 3.8 | 3.7 | 2.3 | 1.9 |
Key Financials and Per-Share Data
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash and equivalents | 1,675 | 963.27 | 903.3 | 1,099 | 1,000 |
Cash and short-term investments | 2,026 | 983.31 | 903.3 | 1,131 | 1,000 |
Accounts receivable | 551.02 | 412.83 | 445.75 | 530.73 | 722.54 |
Inventory | 613.42 | 541.01 | 477.08 | 544.44 | 453.75 |
Goodwill | 41.81 | 41.81 | 41.81 | 41.81 | 41.81 |
Total debt, derived | 150 | 0 | 328 | 335 | 733 |
Net cash (positive = net cash) | 1,876 | 983.31 | 575.54 | 796.42 | 266.64 |
Net cash per share (MYR Bn) | 1.65 | 0.84 | 0.49 | 0.69 | 0.23 |
Cash Flow
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net debt issued (repaid) | -536.3 | -138.4 | 320.33 | -35.38 | 401.24 |
Net change in cash | 891.62 | -284.77 | -159.15 | -234.65 | 316.91 |
Data Point Details
| Data point | Value | Date / source |
|---|---|---|
Share price | RMB 6.56 | 31 Jul 2026, StockAnalysis |
Share price | RMB 5.22 | 13 Jul 2026, STCN |
Share price | RMB 7.81 | 13 Aug 2025, Jiemian |
Share price | RMB 7.24 | May 2025, Simply Wall St |
Share price | Above RMB 10 | 2022, Jiemian |
Market cap, derived | Approx. RMB 7.66bn | 31 Jul 2026 |
P/E on FY2025 EPS, derived | Approx. 87x | 31 Jul 2026 |
P/E on TTM to Q1 2026, derived | Approx. 117x | 31 Jul 2026 |
Analyst coverage | None submitting estimates | Simply Wall St |
Credit ratings | None (no listed bonds) | FY2025 AR: corporate bonds not applicable |
Dividend per share (MYR Bn) | FY2021 | FY2022 |
Cash dividend per share | 0.20 | — |
Analyst Conclusions
Guidance. Management gives no annual targets; the only forward data is the H1 2026 pre-announcement (net profit RMB 220–250M; non-recurring-adjusted RMB 210–240M). There is no sell-side consensus.
Bull case
-
The H1 2026 rebound (Q2 implied RMB 186–216M) suggests run-rate earnings well above FY2025, and FY2021 proved the asset can earn over RMB 2bn at cycle peaks.
-
Downstream VAM/EVA and DMC, if funded at RMB 1.6bn, shift the mix toward higher-value products with import-substitution demand.
-
A strong SOE parent, low leverage and full float since April 2026 provide a stable platform.
Bear case
-
Structural overcapacity (over 15 Mt, with downstream growth of 5–7%) caps mid-cycle margins; FY2023 and FY2025 show how thin trough earnings are.
-
Up to 30% dilution and roughly three-year build times push returns out; the 2025 attempt failed.
-
Licensed technology, falling R&D and related-party flows to the parent weaken the minority-investor case.
Catalysts and monitorables (next 12 months): H1 2026 report detail and Q3 2026 results (late October); shareholder vote, SSE review and CSRC registration of the 2026 placement; acetic acid and coal price spreads; new industry capacity commissioning; any further related-party transactions; FY2026 dividend.
Analyst verdict.
Jiangsu SOPO Chemical, the listed core of the state-owned SOPO Group, is a competently run but structurally challenged commodity producer. Its 1.2-million-tonne acetic acid platform gives genuine scale, and its balance sheet remains conservative, but the five-year record demonstrates that earnings are almost entirely a function of the acetic acid spread rather than company-specific advantage. Gross margin moved from about 42% to about 5% in four years as Chinese capacity surged, and the company has neither coal integration nor proprietary technology to defend returns through the trough.
The 2026 rebound is real but price-driven. If H1 2026 guidance holds, annualised profit could recover toward or above the FY2024 level, yet the stock already trades on a high multiple of depressed trailing earnings, and investors should treat the recovery as cyclical rather than structural.
The investment debate therefore turns on the downstream programme. VAM/EVA and electronic-grade DMC are logical extensions of the methanol and acetic acid chain and address real import-substitution and energy-transition demand. However, the projects rely on licensed foreign technology, enter markets where larger competitors are also adding capacity, require up to 30% dilution, and have a history of delay; the first funding attempt was withdrawn in November 2025. The related-party acquisition of the VAM licence from the parent drew formal minority-investor scrutiny.
On balance, SOPO is a cyclical trading vehicle rather than a compounding equity. The asymmetric upside lies in a sharp acetic acid upturn coinciding with successful placement execution; the downside lies in persistent overcapacity combined with dilution at depressed prices. Monitoring the placement's approval and pricing, quarterly acetic acid realisations, and whether management restores R&D investment will be decisive. Absent sell-side coverage, investors should rely directly on the quarterly operating-data filings, which provide the most timely read on volumes and realised prices.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Notes |
|---|---|---|
Shao Shouyan (邵守言) | Chairman | Chaired 10th board meetings in 2025–2026; director since at least 2020; recused as related director on SOPO Group transactions, indicating a group-level role |
Ma Kehe (马克和) | Director | Director since at least 2020; recused as related director in Feb 2026 |
Chen Zhilin | General Manager / CEO | Per Simply Wall St; not cross-verified |
Hu Zonggui (胡宗贵) | Former director/chairman era (2020 board) | Listed on 2020 placement report |
Fan Liming, Fan Ming | Directors on 2020 board | — |
Kong Yusheng, Wu Junmin | Directors on 2020 board (likely independents) | — |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Jiangsu SOPO (Group) Co., Ltd. | 867,603,652 | 74.29 |
Free float and other holders | approx. 300,239,232 | approx. 25.71 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning |
|---|---|---|
Hualu Hengsheng (600426) | Acetic acid, DMC, coal chemicals | Much larger, lower-cost integrated coal chemical leader |
Shanghai Huayi / Wujing Chemical | Acetic acid, methanol | Large Shanghai SOE |
Yankuang Lunan Chemical (Shandong Energy) | Acetic acid, esters | Coal-integrated |
Celanese (Nanjing) | Acetic acid, VAM, EVA | Global technology leader |
BP-YPC / BP-SECCO JVs | Acetic acid | Multinational JV capacity |
Tianjin Bohai Yongli | Acetic acid | Northern SOE |
Henan Longyu / Shaanxi Yanchang | Acetic acid | Coal-region producers |
Guangxi Huayi | Acetic acid, coal chemicals | Southern capacity |
Wanhua, Rongsheng, Sinopec, Lianhong | VAM / EVA | Future competitors in planned downstream lines |
Shida Shenghua (603026), Oriental Shenghong | DMC / electrolyte solvents | Future competitors in DMC |
Recent Developments
--



